Subscribe To
AQST / Aquestive Therapeutics: Developing A Better Solution To A $1 Billion/Year Anaphylaxis Problem
Content Topics
Aquestive
Therapeutics
Developing
Better
Solution
Therapeutics
Billion year
Anaphylaxis
Problem
Stock
AQST
AQST News
By Zacks Investment Research
November 1, 2023
Aquestive Therapeutics (AQST) Stock Falls Amid Market Uptick: What Investors Need to Know
The latest trading day saw Aquestive Therapeutics (AQST) settling at $1.54, representing a -1.91% change from its previous close. more_horizontal
By Zacks Investment Research
October 9, 2023
Aquestive Therapeutics (AQST) Stock Sinks As Market Gains: Here's Why
Aquestive Therapeutics (AQST) closed at $1.32 in the latest trading session, marking a -0.75% move from the prior day. more_horizontal
By Seeking Alpha
September 22, 2023
ARS Pharmaceuticals Vs. Aquestive Therapeutics; Neffy CRL Creates An Opportunity For Investing In Both
Both ARS Pharmaceuticals and Aquestive Therapeutics are developing non-injectable epinephrine products for anaphylaxis, with potential to capture sign more_horizontal
By Zacks Investment Research
September 13, 2023
Aquestive Therapeutics (AQST) Flat As Market Gains: What You Should Know
Aquestive Therapeutics (AQST) closed at $1.66 in the latest trading session, marking no change from the prior day. more_horizontal
By Zacks Investment Research
September 12, 2023
Aquestive's (AQST) Libervant Accepted for FDA Review, Stock Up
Aquestive (AQST) announces FDA acceptance of a regulatory application seeking approval for Libervant to treat pediatric patients with frequent seizure more_horizontal
By Zacks Investment Research
August 7, 2023
Aquestive Therapeutics (AQST) Reports Q2 Loss, Tops Revenue Estimates
Aquestive Therapeutics (AQST) came out with a quarterly loss of $0.10 per share versus the Zacks Consensus Estimate of a loss of $0.11. This compares more_horizontal
By Zacks Investment Research
July 26, 2023
Aquestive (AQST) to Report Q2 Earnings: What's in Store?
Aquestive's (AQST) second-quarter 2023 revenues are likely to have been driven by rising licensed product revenues. more_horizontal
By Seeking Alpha
July 25, 2023
Aquestive Therapeutics: Developing A Better Solution To A $1 Billion/Year Anaphylaxis Problem
Anaphylm, epinephrine sublingual film is a better solution to existing and in-development epinephrine formulations to treat anaphylaxis, a $1 billion/ more_horizontal